{"id":"https://openalex.org/W4282973804","doi":"https://doi.org/10.1158/1538-7445.am2022-ct242","title":"Abstract CT242: KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation","display_name":"Abstract CT242: KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282973804","doi":"https://doi.org/10.1158/1538-7445.am2022-ct242"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-ct242","doi":"https://doi.org/10.1158/1538-7445.am2022-ct242","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-ct242","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063897579","display_name":"David Sommerhalder","orcid":"https://orcid.org/0000-0002-7033-9064","observed_orcids":["https://orcid.org/0000-0002-7033-9064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Sommerhalder","raw_affiliation_strings":["1NEXT Oncology, San Antonio, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NEXT Oncology, San Antonio, TX;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075591873","display_name":"Jeena Thevathasan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103611","display_name":"Mirati Therapeutics (United States)","ror":"https://ror.org/01by01460","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103611"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeena Thevathasan","raw_affiliation_strings":["2Mirati Therapeutics, Inc., San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mirati Therapeutics, Inc., San Diego, CA;","institution_ids":["https://openalex.org/I4210103611"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024351669","display_name":"Xenophon Ianopulos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103611","display_name":"Mirati Therapeutics (United States)","ror":"https://ror.org/01by01460","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103611"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xenophon Ianopulos","raw_affiliation_strings":["2Mirati Therapeutics, Inc., San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mirati Therapeutics, Inc., San Diego, CA;","institution_ids":["https://openalex.org/I4210103611"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086512125","display_name":"Weining Volinn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103611","display_name":"Mirati Therapeutics (United States)","ror":"https://ror.org/01by01460","country_code":"US","type":"company","lineage":["https://openalex.org/I4210103611"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weining Volinn","raw_affiliation_strings":["2Mirati Therapeutics, Inc., San Diego, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mirati Therapeutics, Inc., San Diego, CA;","institution_ids":["https://openalex.org/I4210103611"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Hong","raw_affiliation_strings":["3University of Texas M.D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3University of Texas M.D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"CT242","last_page":"CT242"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.2395000010728836,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.2395000010728836,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.1949000060558319,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.18729999661445618,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adagrasib","display_name":"adagrasib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9670000076293945},{"id":"https://openalex.org/keywords/kras-g12c-mutation","display_name":"KRAS G12C mutation","score":0.9860000014305115},{"id":"https://openalex.org/keywords/kras-inhibitors","display_name":"KRAS inhibitors","score":0.7440000176429749},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9120000004768372},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.949999988079071},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.7850000262260437},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9890000224113464},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.6539999842643738},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8550000190734863},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7940000295639038},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6970000267028809},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.3050000071525574},{"id":"https://openalex.org/keywords/ras-mapk-pathway","display_name":"RAS/MAPK pathway","score":0.8019999861717224}],"concepts":[{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.9446154832839966},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6055698990821838},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5449714064598083},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5327496528625488},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5232359766960144},{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.49411633610725403},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4685417413711548},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.3755302131175995},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32652348279953003},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3053080439567566},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.1189342737197876},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.11688637733459473},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.10840994119644165}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-ct242","doi":"https://doi.org/10.1158/1538-7445.am2022-ct242","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-ct242","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3202135925","https://openalex.org/W4281629768","https://openalex.org/W4297986300","https://openalex.org/W4366696454","https://openalex.org/W3172183878","https://openalex.org/W4213177438","https://openalex.org/W3097219677","https://openalex.org/W4387811799","https://openalex.org/W4367041654","https://openalex.org/W4394566874"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"KRAS":[2],"is":[3,19,180],"a":[4,51,134,174,181,207,226],"key":[5],"mediator":[6],"of":[7,33,42,55,99,125,195,221,235,245,269,319,368,387],"the":[8,20,148,187,222,236,243,263,270,283,348,388],"RAS/MAPK":[9],"signaling":[10,126],"cascade":[11],"and":[12,16,27,37,58,63,85,97,116,121,167,191,238,252,265,309,323],"promotes":[13],"cellular":[14,131],"growth":[15],"proliferation.":[17,132],"It":[18],"most":[21],"frequently":[22],"mutated":[23],"oncogene":[24],"in":[25,31,38,66,105,156,197,201,347,371,375],"cancer,":[26],"KRASG12C":[28,62,112,157,208,382],"mutations":[29],"occur":[30],"3-4%":[32],"colorectal":[34],"cancers":[35,45],"(CRC)":[36],"up":[39],"to":[40,61,130,150,229,260],"14%":[41],"non-small-cell":[43],"lung":[44],"(NSCLC).":[46],"The":[47,218],"investigational":[48],"agent":[49,172],"adagrasib,":[50],"potent,":[52],"covalent":[53],"inhibitor":[54],"KRASG12C,":[56],"irreversibly":[57],"selectively":[59],"binds":[60],"locks":[64],"it":[65],"its":[67],"inactive":[68],"state.":[69],"Adagrasib":[70],"was":[71],"optimized":[72],"for":[73,242,391],"favorable":[74],"pharmacokinetic":[75],"(PK)":[76],"properties,":[77],"including":[78],"long":[79],"half-life":[80],"(~24":[81],"h),":[82],"dose-dependent":[83],"PK,":[84,189],"central":[86],"nervous":[87],"system":[88],"penetration.":[89],"Initial":[90],"results":[91],"have":[92],"shown":[93],"encouraging":[94],"antitumor":[95,162],"activity":[96,163,194,268,312],"tolerability":[98],"adagrasib":[100,166,196,246,369],"monotherapy":[101],"or":[102,109,277,338],"combination":[103,198,244,302,372],"therapy":[104],"patients":[106,202,376],"with":[107,170,199,203,212,254,373,377,381],"CRC":[108],"NSCLC":[110],"harboring":[111,206],"mutations.":[113],"Cyclin":[114],"D1":[115],"cyclin-dependent":[117],"kinases":[118],"(CDK)":[119],"4":[120],"6":[122],"are":[123],"downstream":[124],"pathways":[127],"that":[128],"lead":[129],"Palbociclib,":[133],"CDK4/6":[135],"inhibitor,":[136],"disrupts":[137],"cancer":[138],"cell":[139,143],"proliferation":[140],"by":[141,146],"inducing":[142],"cycle":[144],"arrest":[145],"preventing":[147],"G1":[149],"S":[151],"phase":[152,183,365],"transition.":[153],"Preclinical":[154],"data":[155],"mouse":[158],"models":[159],"suggest":[160],"enhanced":[161],"when":[164],"combining":[165],"palbociclib":[168,200,374],"compared":[169],"either":[171],"as":[173,258],"monotherapy.":[175],"Trial":[176],"Design:":[177],"KRYSTAL-16":[178],"(NCT05178888)":[179],"multicenter":[182],"I/Ib":[184,366],"trial":[185,223,367],"evaluating":[186],"safety,":[188,293],"pharmacodynamics,":[190],"preliminary":[192,266,310],"clinical":[193,267,311],"solid":[204,379],"tumors":[205,380],"mutation":[209,383],"previously":[210],"treated":[211],"at":[213,345],"least":[214],"1":[215],"standard":[216],"therapy.":[217],"first":[219],"stage":[220],"will":[224,240,279,327,342],"comprise":[225],"PK":[227,307],"lead-in":[228],"evaluate":[230,262],"potential":[231],"drug-drug":[232],"interactions.":[233],"Exploration":[234],"dose":[237,248,274,296,303],"regimen":[239,304],"continue":[241],"(starting":[247],"400":[249],"mg":[250],"BID)":[251],"palbociclib,":[253],"expansion":[255],"cohorts":[256],"implemented":[257],"applicable":[259],"further":[261],"safety":[264],"combination.":[271],"Decisions":[272],"regarding":[273],"escalation,":[275],"expansion,":[276],"de-escalation":[278],"be":[280,343],"determined":[281],"using":[282],"modified":[284],"Toxicity":[285],"Probability":[286],"Interval":[287],"(mTPI-2)":[288],"design.":[289],"Study":[290],"endpoints":[291],"include":[292],"maximum":[294],"tolerated":[295],"(MTD)":[297],"and/or":[298],"recommended":[299],"Phase":[300],"II":[301],"(RP2D),":[305],"plasma":[306],"parameters,":[308],"(objective":[313],"response":[314],"rate":[315],"[RECIST":[316],"v1.1],":[317],"duration":[318],"response,":[320],"progression-free":[321],"survival,":[322],"overall":[324],"survival).":[325],"Patients":[326],"receive":[328],"treatment":[329],"until":[330],"disease":[331],"progression,":[332],"unacceptable":[333],"adverse":[334],"events,":[335],"patient":[336],"withdrawal,":[337],"death.":[339],"This":[340],"study":[341],"enrolling":[344],"sites":[346],"United":[349],"States.":[350],"Citation":[351],"Format:":[352],"David":[353,361],"Sommerhalder,":[354],"Jeena":[355],"Thevathasan,":[356],"Xenophon":[357],"Ianopulos,":[358],"Weining":[359],"Volinn,":[360],"Hong.":[362],"KRYSTAL-16:":[363],"A":[364],"(MRTX849)":[370],"advanced":[378],"[abstract].":[384],"In:":[385],"Proceedings":[386],"American":[389],"Association":[390],"Cancer":[392,403],"Research":[393],"Annual":[394],"Meeting":[395],"2022;":[396],"2022":[397],"Apr":[398],"8-13.":[399],"Philadelphia":[400],"(PA):":[401],"AACR;":[402],"Res":[404],"2022;82(12_Suppl):Abstract":[405],"nr":[406],"CT242.":[407]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2022-06-17T00:00:00"}